Collaboration is our greatest scientific achievement

Transformative discovery becomes reality by sharing our collective knowledge with those who also bring pioneering, groundbreaking, and often life-changing research to the patient and medical communities. The work we do is too important not to share, collaborate on, and draw strength from.

Immune tolerization

Determining efficacy of tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses to AAV therapeutics.

Patient redosing

Joint partnership to develop, manufacture, and commercialize targeted therapeutics for a human proof of concept trial to validate the potential for redosing.

In vivo genome editing

Exploring in vivo delivery of genome editing medicines to treat neurological diseases affecting patients with high unmet need.

cGMP Manufacturing

Using Pro10™ technology to manufacture AAV in a state-of-the-art facility for a flexible, scalable AAV manufacturing system.

Doggybone™ DNA (dbDNA™)

As a replacement for plasmid DNA, Doggybone™ DNA is a synthetic DNA that is safer and can be produced with greater efficacy.

Chimeric Capsids

Rationally designed chimeric AAV capsids enable efficient gene delivery with immunological properties for a precise tissue target.

Institutional research partnerships

AskBio is proud to advance genetic medicine with the world’s most respected institutional laboratories and medical programs. Our shared goal is to expand possibilities for the scientific community and gene therapy industry that will advance patient care and bring cures to those who need them most.

  • University of North Carolina
  • Duke University
  • University of Texas
  • University of Iowa
  • University of Florida
  • Ohio State University
  • University of Washington
  • University of Nantes
  • Inserm
  • Queens College
  • Mount Sinai Hospital
  • Massachusetts General Hospital
  • University of California – SF
  • Yale University
  • Harvard University

Ask David

“When Synpromics was acquired by AskBio, it opened new doors for revolutionizing the precise expression of gene therapeutics.”

David Venables, PhD
President, AskBio Europe

Are you our next great collaborator?

Harness the power of our technology, scientific expertise, and clinical process experience to bring discoveries to life.